文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

在新辅助放化疗+全直肠系膜切除术时代,直肠癌中侧方淋巴结受累带来了另一个挑战:生存结果评估。

Lateral lymph node involvement presents another challenge in rectum cancer in the age of neoadjuvant chemoradiotherapy + total mesorectal excision: an evaluation of survival outcomes.

机构信息

Department of General Surgery, Section of Gastroenterological Surgery, Ankara Etlik City Hospital, Ankara, Turkey.

Department of Radiology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey.

出版信息

Langenbecks Arch Surg. 2023 Sep 13;408(1):356. doi: 10.1007/s00423-023-03101-1.


DOI:10.1007/s00423-023-03101-1
PMID:37702958
Abstract

PURPOSE: In the last decades, total mesorectal excision (TME) and neoadjuvant chemoradiotherapy (nCRT) have produced an undeniable improvement in the treatment of rectal cancer. However, local recurrence is still an important problem, and the effect of lateral lymph node (LLN) involvement on local recurrence is a controversial issue. The aim of this study was to investigate the effects of LLN status on local recurrence and survival in rectal cancers treated with nCRT + TME. METHODS: Clinical features, pre- and post-nCRT lateral pelvic region imaging, long-term local recurrence, and the survival outcomes of 114 patients who underwent nCRT + TME for rectal cancer were evaluated. RESULTS: On MRI before nCRT, 20 (17.5%) patients had lateral lymph nodes (LLN+), and 94 (82.5%) patients had no lymph nodes in the lateral pelvic compartments (LLN-). Local recurrences at 1 year in LLN+ and LLN- patients were 3 (15.8%) and 2 (2.3%), respectively (p=0.039). Five-year local recurrence-free survival rates and the mean duration of recurrence-free survival in LLN+ and LLN- patients were 56.2%, 42.6 months, and 87.3% 66.9 months, respectively (p=0.001). Disease-free survival and overall survival were shorter in LLN+ patients, but the difference was not statistically significant (p=0.096 and p=0.46, respectively). In the multivariate analysis, LLN involvement was determined to be an independent risk factor for local recurrence-free survival (Hazard Ratio 4.54, p=0.003). CONCLUSION: Lateral lymph node involvement causes local recurrence to remain high after nCRT + TME. LLN status should be considered in treatment planning. Further studies are needed to define precise criteria for LLN involvement and the effect of LLND on local recurrence and survival.

摘要

目的:在过去的几十年中,全直肠系膜切除术(TME)和新辅助放化疗(nCRT)在直肠癌的治疗中取得了不可否认的改善。然而,局部复发仍然是一个重要的问题,侧方淋巴结(LLN)受累对局部复发的影响是一个有争议的问题。本研究旨在探讨 nCRT+TME 治疗直肠癌时 LLN 状态对局部复发和生存的影响。

方法:评估了 114 例接受 nCRT+TME 治疗的直肠癌患者的临床特征、nCRT 前后侧盆腔区域影像学、长期局部复发和生存结果。

结果:在 nCRT 前的 MRI 上,20 例(17.5%)患者有侧方淋巴结(LLN+),94 例(82.5%)患者无侧盆腔淋巴结(LLN-)。LLN+和 LLN-患者的 1 年局部复发率分别为 3 例(15.8%)和 2 例(2.3%)(p=0.039)。LLN+和 LLN-患者的 5 年局部无复发生存率和无复发生存期的平均值分别为 56.2%、42.6 个月和 87.3%、66.9 个月(p=0.001)。LLN+患者的无病生存率和总生存率较短,但差异无统计学意义(p=0.096 和 p=0.46)。在多变量分析中,LLN 受累被确定为局部无复发生存的独立危险因素(风险比 4.54,p=0.003)。

结论:nCRT+TME 后,侧方淋巴结受累导致局部复发率仍然较高。在治疗计划中应考虑 LLN 状态。需要进一步研究以确定 LLN 受累的精确标准以及 LLND 对局部复发和生存的影响。

相似文献

[1]
Lateral lymph node involvement presents another challenge in rectum cancer in the age of neoadjuvant chemoradiotherapy + total mesorectal excision: an evaluation of survival outcomes.

Langenbecks Arch Surg. 2023-9-13

[2]
The influence of neoadjuvant chemoradiotherapy combined with lateral lymph nodes dissection or not on the local recurrence of low to intermediate-stage II/III rectal cancer.

J Surg Oncol. 2024-2

[3]
Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer.

World J Gastroenterol. 2020-6-7

[4]
Lateral pelvic lymph node dissection after neoadjuvant chemo-radiation for preoperative enlarged lateral nodes in advanced low rectal cancer: study protocol for a randomized controlled trial.

Trials. 2016-11-25

[5]
Preoperative lateral lymph node features and impact on local recurrence after neoadjuvant chemoradiotherapy and total mesorectal excision for locally advanced rectal cancer: results from a multicentre international cohort study.

Colorectal Dis. 2024-3

[6]
Systematic review and meta-analysis of long-term oncological outcomes of lateral lymph node dissection for metastatic nodes after neoadjuvant chemoradiotherapy in rectal cancer.

Eur J Surg Oncol. 2022-7

[7]
Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer.

BJS Open. 2019-7-25

[8]
Local recurrences in western low rectal cancer patients treated with or without lateral lymph node dissection after neoadjuvant (chemo)radiotherapy: An international multi-centre comparative study.

Eur J Surg Oncol. 2021-9

[9]
Lateral lymph node dissection reduces local recurrence of locally advanced lower rectal cancer in the absence of preoperative neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.

World J Surg Oncol. 2020-11-23

[10]
Optimization of therapeutic strategies for selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in patients with rectal cancer with clinical suspected lateral lymph node metastasis.

Front Oncol. 2023-10-10

引用本文的文献

[1]
MRI for prognosis prediction of T3-stage rectal cancer based on "DISTANCE" structural report.

Abdom Radiol (NY). 2025-8-9

[2]
The Role of Lateral Pelvic Lymph Node Dissection in Middle and Lower Rectal Cancer (Stage II or III): A Literature Review.

Cureus. 2024-8-22

[3]
Prognostic value of lateral lymph node metastasis in pretreatment MRI for rectal cancer in patients undergoing neoadjuvant chemoradiation followed by surgical resection without lateral lymph node dissection: A systemic review and meta-analysis.

Eur J Radiol. 2024-9

[4]
Quality assessment of surgery for colorectal cancer: Where do we stand?

World J Gastrointest Surg. 2024-4-27

本文引用的文献

[1]
Lateral lymph node dissection in advanced low rectal cancer treatment.

Int J Colorectal Dis. 2021-11

[2]
Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer.

J Clin Oncol. 2018-11-7

[3]
What To Do With Lateral Nodal Disease in Low Locally Advanced Rectal Cancer? A Call for Further Reflection and Research.

Dis Colon Rectum. 2017-6

[4]
Oncological Outcomes of Lateral Pelvic Lymph Node Metastasis in Rectal Cancer Treated With Preoperative Chemoradiotherapy.

Dis Colon Rectum. 2017-5

[5]
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.

Int J Clin Oncol. 2018-2

[6]
Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial.

Ann Surg. 2017-8

[7]
Prediction of Lateral Pelvic Lymph-Node Metastasis in Low Rectal Cancer by Magnetic Resonance Imaging.

World J Surg. 2016-4

[8]
Can chemoradiation allow for omission of lateral pelvic node dissection for locally advanced rectal cancer?

J Surg Oncol. 2015-3-15

[9]
Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid/low rectal cancer with clinically suspected lateral node involvement: a multicenter retrospective cohort study.

Ann Surg Oncol. 2014-7

[10]
Factors associated with lateral pelvic recurrence after curative resection following neoadjuvant chemoradiotherapy in rectal cancer patients.

Int J Colorectal Dis. 2013-12-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索